Webcast overview
The life sciences industry is on the cusp of a transformative era, driven by the integration of Generative AI solutions. These advanced technologies are poised to revolutionize regulatory decision-making, ensuring the safety, effectiveness, and quality of life sciences products. However, with this innovation comes the need for clear and robust guidelines. The U.S. Food and Drug Administration (FDA) has recently published draft guidance, 鈥淐onsiderations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products鈥�, to address the use of AI in regulatory processes.
Join us for an insightful webcast, co-hosted by 乐鱼（Leyu）体育官网 and ValKit.ai, where we will delve into the implications and practical applications of this guidance.
Our Speakers:
- Madhavi Ganesan,聽Life Sciences Director at 乐鱼（Leyu）体育官网 LLP
- Dr. Paul Campbell, Chief Regulatory Officer, HealthAI (Former MHRA)
- Dr. Laura Rose, Engagement Partner, Bruder Consulting & Venture Group (Former FDA)
- Stephen Robert Ferrell, Chief Product Officer, Valkit.ai
- Louie Rayal, VP of Governance, Risk & Compliance at GSK
